Email this page
Print this pageWashington, DC - January 21, 2009 - The independent Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, supported by the National Office of Public Health Genomics at the Centers for Disease Control and Prevention, has released new evidence-based recommendations on the validity and utility of three genetic tests currently being used in clinical practice. The tests are tumor expression profiling in patients with breast cancer to inform treatment options, UGT1A1 genotyping for metastatic colorectal cancer to inform drug dosage, and genetic testing for Lynch syndrome mutation in newly diagnosed colorectal cancer patients to alert the patient's relatives about their potential risk if they carry the same mutation.
The recommendations are published in the January 2009 issue of the journal Genetics in Medicine and can be accessed through the EGAPP Web site or from the GPPC bibliography. EGAPP said it could recommend offering genetic testing for Lynch syndrome to colorectal cancer patients, but said there was not enough information available for breast cancer tumor expression profiling or UGT1A1 genotyping to recommend for or against use of these genetic tests in clinical practice.
GPPC's deputy director, Joan Scott, serves as a member of the EGAPP Working Group and a coauthor of the three papers.
Related article - EGAPP panel releases first recommendations, discourages CYP450 testing
For More Information Contact:
<< Back to News Releases
